Nano-X Imaging increased first-quarter revenue and placed its Nanox.ARC at a RadNet site, but slow activations, withdrawn guidance and a going-concern warning leave the medical imaging company facing a difficult commercial test.
CONNEQT Health is seeking an FDA pathway for cloud-based arterial analytics, but regulatory execution, customer integration, cash burn and a heavily dilutive capital raise complicate the ASX micro-cap opportunity.
See how One Biosciences is using single-cell profiling to improve ADC biomarkers, patient selection and future companion diagnostics.
Galmed Pharmaceuticals has acquired Colospan and its CG-100 colorectal bypass device, but European adoption, pivotal United States evidence and financing will determine whether the micro-cap company can create a sustainable medtech business.
FDA clearance for contactless respiratory-rate measurement expands PanopticAI’s regulated digital-health platform, but restricted use, cloud dependence and uncertain reimbursement remain major commercial tests.
IceCure Medical’s FDA-authorised breast cancer cryoablation platform is gaining United States installations, but narrow eligibility, postmarket evidence requirements and heavy dilution complicate the small-cap investment case.
Discover how Premier Biotech’s NexScreen and TransMed acquisitions expand point-of-care testing, e-commerce and global diagnostics reach.
Discover how Greenstone Biosciences and Intel plan to scale iPSC drug discovery, and why validation will determine the platform’s impact.
FDA clearance to begin the RELIEF study opens a large benign prostatic hyperplasia opportunity for NanoKnife, but the small trial, general anaesthesia and crowded treatment market leave major commercial questions unanswered.
Read how Alberta’s September 2026 dual-practice surgery model could reshape capacity, staffing, private payment and patient access.